8-K: Humana's Medicare Advantage Star Ratings Plunge, Impacting Future Revenue

Humana reports a significant drop in its Medicare Advantage Star Ratings for 2025, with only 25% of members in 4-star or higher plans, down from 94% in 2024, impacting future bonus payments.

Summary

• Humana's Medicare Advantage Star Ratings for 2025 have significantly decreased, with only 25% of members in plans rated 4 stars and above, compared to 94% in 2024.
• This decline is primarily due to contract H5216 dropping from a 4.5-star to a 3.5-star rating, which affects 45% of Humana's MA membership.
• The lower star ratings will negatively impact Humana's quality bonus payments in 2026.
• Humana believes there may be errors in CMS's calculations and is appealing the results.
• The company is implementing initiatives to improve its star ratings, focusing on member and provider engagement, customer experience, and technology integration.
• Humana is exploring options to mitigate the expected revenue impact in 2026.
• The 2025 Star ratings are not expected to impact the company's financial results or outlook for 2024 or 2025.
• There is now more risk in Humana's ability to achieve its individual MA margin target of at least 3 percent by 2027.

Sentiment

Score: 3

Explanation: The document conveys a negative sentiment due to the significant drop in star ratings and the potential impact on future revenue and profitability. While the company is taking steps to address the issues, the overall tone is one of disappointment and concern.

Positives

• Humana is actively appealing the preliminary star rating results and believes there may be errors in the calculations.
• The company has initiatives underway to improve its operating discipline and return to an industry-leading Stars position.
• These initiatives are expected to improve quality bonus payments in 2027 and beyond.
• The 2025 Star ratings are not expected to impact the company's financial results or outlook for 2024 or 2025.
• Humana is focused on realizing its full potential by concentrating on continuous improvement and leveraging its differentiated capabilities.

Negatives

• Humana's Medicare Advantage Star Ratings for 2025 have significantly decreased, with only 25% of members in 4-star or higher plans.
• The decline in star ratings will negatively impact Humana's quality bonus payments in 2026.
• There is now more risk in Humana's ability to achieve its individual MA margin target of at least 3 percent by 2027.

Risks

• The reduction in Star ratings will negatively impact Humana's quality bonus payments in 2026.
• There is a risk that Humana's appeals to CMS will be unsuccessful, leading to a revenue headwind in 2026.
• There is increased risk in the company's ability to achieve its individual MA margin target of at least 3 percent by 2027.
• The company's initiatives to improve star ratings may not be as effective as anticipated.

Future Outlook

Humana expects its initiatives to improve star ratings to positively impact bonus payments in 2027 and beyond, and is exploring options to mitigate the expected 2026 revenue headwind. The company remains focused on achieving its individual MA margin target of at least 3 percent, although there is now more risk in its ability to fully achieve this result by 2027.

Management Comments

• The Company is disappointed with its performance and has initiatives underway focused on improving its operating discipline and returning to an industry leading Stars position as quickly as possible.
• Humana is exploring all available options to mitigate the expected 2026 revenue headwind related to its 2025 Star ratings in the event its challenges to the results are unsuccessful.
• The Company remains focused on achieving its individual MA margin target of at least 3 percent, although there is now more risk in its ability to fully achieve this result by 2027.

Industry Context

The decline in Humana's star ratings highlights the competitive and challenging nature of the Medicare Advantage market, where quality ratings directly impact revenue through bonus payments. This could put pressure on other insurers to maintain or improve their own ratings.

Comparison to Industry Standards

• The document does not provide specific details on the performance of other companies, but it does mention that Humana narrowly missed higher industry cut points on a small number of measures.
• This suggests that other companies may have performed better on these measures, leading to higher star ratings.
• The document does not provide specific details on the performance of other companies, but it does mention that Humana narrowly missed higher industry cut points on a small number of measures.
• This suggests that other companies may have performed better on these measures, leading to higher star ratings.
• Companies like UnitedHealth Group and CVS Health (Aetna) are major players in the Medicare Advantage market and are likely to be closely watched for their star ratings performance.
• The document does not provide specific details on the performance of other companies, but it does mention that Humana narrowly missed higher industry cut points on a small number of measures.
• This suggests that other companies may have performed better on these measures, leading to higher star ratings.

Stakeholder Impact

• Shareholders may be concerned about the potential impact on future revenue and profitability.
• Members may be affected by changes in plan quality and benefits.
• Employees may be impacted by the company's efforts to improve star ratings.

Next Steps

• Humana will continue to engage with CMS on the Star ratings results.
• The company will provide additional detail regarding its initiatives to improve star ratings over the coming months.
• Humana will explore all available options to mitigate the expected 2026 revenue headwind.

Key Dates

Keywords

Medicare Advantage, Star Ratings, CMS, Quality Bonus Payments, Healthcare, Health Insurance, Humana, Member Engagement, Provider Engagement, Customer Experience